This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The World Market For Stents (Drug-Eluting And Bare Metal Product Markets In US, EU, Japan, India, China And ROW)


MGuard Prime





Bioresorbable Stents


Drawbacks of Bioresorbable Polymeric Stents


Selected Bioresorbable Coronary Stents

The Absorb stent


Biotronik's Dreams stent


DESolve stent


ReZolve Stent


IDEAL stent


Other bioresorbable stents




Lesion Specific Stents

Dedicated Bifurcated Stents



Nile Pax


Stentys Self-Apposing stent


Taxus Petal


Xience Side Branch Access




Taxus Liberte Atom


Xience nano





Sales and Marketing Capabilities


Differentiation Strategies

Improved Stent Materials


Reduced DAPT Duration



Lesion-Specific Stents

Extended Indications



Significant Trends In The Coronary Stents Market



Market Drivers

New devices Expanded Indications

Acute Myocardial Infarction and Diabetes



Emerging Markets Are Expected To Spur The Overall Market Growth.



Market Restraints

Price decline hampers growth in the overall market.


Cost Constraints


Difficult Economic Conditions



Notable Recent Industry Events

Recent Mergers and Acquisitions

Biosensors International acquired CardioMind and Devax


Medtronic Acquired Invatec


Xenogenics Corporation Acquired Bioabsorbable Therapeutics



Market Exits





Market by Type of Stent

Drug Eluting Stents Market

Market Snapshot



Products Analysis

Xience V


Promus Element/Plus


Resolute Integrity


Market Dynamics in the Drug-Eluting Stents Segment




Revenue Forecast

Bare Metal Stents Market

Market Snapshot


Market Dynamics


Revenue Forecast



United States

Market Snapshot


Revenue Forecast




Market snapshot


Revenue Forecast




Market snapshot


Revenue forecast




Market Snapshot


Revenue forecast




Market snapshot


Revenue Forecast



3 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs